Keywords: Amgen, Denosumab, Xgeva, Prolia, one metastases, USA, FDA

US FDA approves expanded use of Amgen’s bone drug denosumab, which could boost potential sales to $2.4 billion

Article | 19 November 2010

Print This

The US Food and Drug Administration yesterday approved global biotech leader Amgen’s (Nasdaq: AMGN) Xgeva (denosumab), the first ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in